Your browser doesn't support javascript.
loading
Lambert-eaton myasthenic syndrome.
Weimer, Maria B; Wong, Joaquin.
Afiliación
  • Weimer MB; Maria B. Weimer, MD Louisiana State University Health Sciences Center, Department of Neurology, 200 Henry Clay Suite 3314, New Orleans, LA 70118, USA. mweime@lsuhsc.edu.
Curr Treat Options Neurol ; 11(2): 77-84, 2009 Mar.
Article en En | MEDLINE | ID: mdl-19210909
ABSTRACT
Lambert Eaton myasthenic syndrome (LEMS) is a rare neuromuscular junction disease. Often, the signs and symptoms of LEMS are mistaken for myasthenia gravis and therefore the workup is misdirected. A physician must look for an occult malignancy when the diagnosis is made and then continue to search for a malignancy for at least 5 years after diagnosis. The diagnosis of LEMS can be confirmed with electrophysiologic studies or with serum calcium channel antibodies. In most patients with LEMS, 3,4-diaminopyridine will improve strength. In patients without malignancy, immunosuppressants do have a role in the treatment of LEMS. Patients and physicians must be aware that certain situations and drugs may exacerbate weakness.
Buscar en Google
Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Curr Treat Options Neurol Año: 2009 Tipo del documento: Article País de afiliación: Estados Unidos
Buscar en Google
Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Curr Treat Options Neurol Año: 2009 Tipo del documento: Article País de afiliación: Estados Unidos